MedTrace Logo

Diagnostic Accuracy and Performance of 18F-PSMA-1007

NCT04986280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 174

Last updated 2024-06-07

No results posted yet for this study

Summary

Whereas 18F-PSMA-1007 has rapidly established itself as a radiotracer for the investigation of prostate cancer, there are no studies confirming its diagnostic performance. The purpose of this study is to determine the diagnostic performance for this radiotracer.

Conditions

Interventions

DIAGNOSTIC_TEST

[18F]PSMA-1007

PSMA PET/CT using the intervention.

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Ali Afshar-Oromieh, MD · Deputy Clinic Director

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-13
Primary Completion
2022-09-12
Completion
2024-03-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04986280 on ClinicalTrials.gov